The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations.
Participation in the study will last approximately 155 days.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-08; most recent amendment 2026-01-21.
Status change: Active, Not Recruiting → Completed2026-01-21
Status change: Recruiting → Active, Not Recruiting2025-09-25